eFFECTOR Therapeutics is working to develop better medicines to treat cancer. Cancer is a complex and aggressive disease that is driven by genetic mutations that enable cells to evade existing therapeutics. To overcome this, eFFECTOR is pioneering a new class of drugs called selective translational regulator inhibitors (STRIs). STRIs work via various mechanisms from augmenting the efficacy of existing therapies to targeting immune suppression factors and resistance mechanisms. eFFECTOR’s lead STRI candidate, tomivosertib, is a potent and highly selective MNK inhibitor to downregulate immune suppressive responses. Tomivosertib has shown promising Phase 2a clinical trial results and is now being initiated in Phase 2b.

eFFECTOR Therapeutics

Short description:

Drug notes:

Long description:

Jobs: